Not all patients with CLL call for therapy. Inspite of all modern innovations, the iwCLL nevertheless suggests watchful observation for clients with asymptomatic disease.86 This recommendation relies on a minimum of two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).Na